Alnylam and Collaborators Publish Results from Phase I Clinical Trial with RNAi Therapeutic

News   Jan 31, 2013

 
Alnylam and Collaborators Publish Results from Phase I Clinical Trial with RNAi Therapeutic
 
 
 

RELATED ARTICLES

Sphere Fluidics and Geneva Biotech Receive Eurostars Genome Editing Grant

News

€1.6 million grant will support ‘precise docking of very large DNA cargoes in genomes’ project.

READ MORE

RNAi-based Drug Shows Promise as Treatment for Chronic Hepatitis B

News

The novel therapy by Arrowhead Pharmaceuticals uses a mechanism called RNA interference to reduce the surface antigens created by chronic HBV infections.

READ MORE

A More Effective Alternative to RNAi, CRISPR for Studying Protein Function

News

Trim-Away is a novel method enabling researchers to directly and rapidly destroy any protein in any kind of cell.

READ MORE

 

Comments | 0 ADD COMMENT

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE